Home › NDC Lookup › RxCUI directory › RxCUI 1648785

14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhale... — RxCUI 1648785

Name: 14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder I… (RxCUI 1648785)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1648785 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1648785

Official name14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Breo]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asBreo Ellipta (fluticasone furoate 200 MCG/ACTUAT / vilanterol 25 MCG/ACTUAT) Dry Powder Inhaler, 14 ACTUAT; Breo Ellipta 200/25 MCG/INHAL Dry Powder Inhaler, 14 Blisters; Breo Ellipta (fluticasone furoate 200 MCG/ACTUAT / vilanterol 25 MCG/ACTUAT (as vilanterol trifenatate 40 MCG/ACTUAT)) Dry Powder Inhaler, 14 ACTUAT

FDA products mapped3

Package NDCs mapped5

Reported Medicaid activity (SDUD)85,370 prescriptions · 46 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Fluticasone Oral Inhalation: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It helps prevent asthma symptoms when used every day. It is for adults and children aged 4 and older. It will not stop a sudden attack, so keep your quick-relief inhaler with you.
Not right away. Some people feel better sooner, but full benefit can take 1 to 2 weeks or longer. Keep using it as prescribed even if you feel fine.
You breathe it in by mouth, usually twice a day about 12 hours apart. Prime it before first use and again if you have not used it in over 7 days or dropped it. Rinse your mouth wit...
Common ones include throat irritation, colds or sinus symptoms, cough and headache. Thrush in the mouth can happen, and rinsing helps. Call your doctor if you see white patches or...

📖 Read our full Fluticasone Oral Inhalation guide →

🕸️ Concept Web — How 14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vi... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Breo] RxCUI 1648785 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 4

The active substance itself — no strength, form, or brand attached yet.
- Fluticasone 41126 IN
- Vilanterol 1424884 IN
- Fluticasone / vilanterol 1424888 MIN
- Fluticasone furoate 705022 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Breo 1539887 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Fluticasone / vilanterol Dry Powder Inhaler 1424887 SCDF
- Fluticasone furoate / vilanterol Dry Powder Inhaler 2646015 SCDFP
- Fluticasone / vilanterol Inhalant Product 1424886 SCDG
- Fluticasone furoate / vilanterol Inhalant Product 2663172 SCDGP
- Fluticasone / vilanterol Dry Powder Inhaler [Breo] 1539889 SBDF
- Fluticasone furoate / vilanterol Dry Powder Inhaler [Breo] 2654180 SBDFP
- Breo Inhalant Product 1539890 SBDG
- Dry Powder Inhaler 744995 DF
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler 1648783 SCD
- Fluticasone furoate 0.2 MG/ACTUAT 1547665 SCDC
- Vilanterol 0.025 MG/ACTUAT 1424885 SCDC
- Fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT [Breo] 1648784 SBDC

Showing up to 8 concepts per family — 17 of 18 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

14 ACTUAT fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler SCD · 1648783
Fluticasone furoate 0.2 MG/ACTUAT SCDC · 1547665
Vilanterol 0.025 MG/ACTUAT SCDC · 1424885
Fluticasone / vilanterol Dry Powder Inhaler SCDF · 1424887
Fluticasone furoate / vilanterol Dry Powder Inhaler SCDFP · 2646015
Fluticasone / vilanterol Inhalant Product SCDG · 1424886
Fluticasone furoate / vilanterol Inhalant Product SCDGP · 2663172

Brand-Name Concepts

Fluticasone furoate 0.2 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT [Breo] SBDC · 1648784
Fluticasone / vilanterol Dry Powder Inhaler [Breo] SBDF · 1539889
Fluticasone furoate / vilanterol Dry Powder Inhaler [Breo] SBDFP · 2654180
Breo Inhalant Product SBDG · 1539890
Breo BN · 1539887

📦 FDA Products & Package NDCs

3 products · 5 package NDCs

5 package NDCs map to RxCUI 1648785 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00173-0859-10	1 TRAY in 1 CARTON (0173-0859-10) / 1 INHALER in 1 TRAY / 3...	Breo Ellipta	GlaxoSmithKline LLC	2013-08-26
00173-0859-14	1 TRAY in 1 CARTON (0173-0859-14) / 1 INHALER in 1 TRAY / 1...	Breo Ellipta	GlaxoSmithKline LLC	2013-08-26
00173-0882-10	1 TRAY in 1 CARTON (0173-0882-10) / 1 INHALER in 1 TRAY / 3...	Breo Ellipta	GlaxoSmithKline LLC	2015-04-30
00173-0882-14	1 TRAY in 1 CARTON (0173-0882-14) / 1 INHALER in 1 TRAY / 1...	Breo Ellipta	GlaxoSmithKline LLC	2015-04-30
00173-0916-10	1 TRAY in 1 CARTON (0173-0916-10) / 1 INHALER in 1 TRAY / 3...	Breo Ellipta	GlaxoSmithKline LLC	2023-05-12

Observed labelers: GlaxoSmithKline LLC (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.